X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ABBOTT INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ABBOTT INDIA NOVARTIS/
ABBOTT INDIA
 
P/E (TTM) x 440.6 40.6 1,085.4% View Chart
P/BV x 31.1 10.8 287.9% View Chart
Dividend Yield % 1.5 0.6 230.0%  

Financials

 NOVARTIS   ABBOTT INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ABBOTT INDIA
Mar-18
NOVARTIS/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7586,110 12.4%   
Low Rs5793,996 14.5%   
Sales per share (Unadj.) Rs228.41,552.2 14.7%  
Earnings per share (Unadj.) Rs31.7188.8 16.8%  
Cash flow per share (Unadj.) Rs32.8196.4 16.7%  
Dividends per share (Unadj.) Rs10.0055.00 18.2%  
Dividend yield (eoy) %1.51.1 137.4%  
Book value per share (Unadj.) Rs297.1796.6 37.3%  
Shares outstanding (eoy) m24.6921.25 116.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.3 89.9%   
Avg P/E ratio x21.126.8 78.7%  
P/CF ratio (eoy) x20.425.7 79.3%  
Price / Book Value ratio x2.26.3 35.5%  
Dividend payout %31.529.1 108.2%   
Avg Mkt Cap Rs m16,505107,376 15.4%   
No. of employees `0000.73.3 20.1%   
Total wages/salary Rs m1,4453,937 36.7%   
Avg. sales/employee Rs Th8,441.39,929.3 85.0%   
Avg. wages/employee Rs Th2,163.61,185.1 182.6%   
Avg. net profit/employee Rs Th1,173.11,207.7 97.1%   
INCOME DATA
Net Sales Rs m5,63932,985 17.1%  
Other income Rs m1,7181,170 146.9%   
Total revenues Rs m7,35734,155 21.5%   
Gross profit Rs m-635,245 -1.2%  
Depreciation Rs m25162 15.6%   
Interest Rs m5538 144.8%   
Profit before tax Rs m1,5756,215 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,203 35.9%   
Profit after tax Rs m7844,012 19.5%  
Gross profit margin %-1.115.9 -7.0%  
Effective tax rate %50.335.4 141.8%   
Net profit margin %13.912.2 114.2%  
BALANCE SHEET DATA
Current assets Rs m9,52222,655 42.0%   
Current liabilities Rs m3,2966,681 49.3%   
Net working cap to sales %110.448.4 228.0%  
Current ratio x2.93.4 85.2%  
Inventory Days Days3765 56.5%  
Debtors Days Days2829 97.5%  
Net fixed assets Rs m46835 5.5%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m7,21316,715 43.2%   
Net worth Rs m7,33616,928 43.3%   
Long term debt Rs m00-   
Total assets Rs m11,10524,162 46.0%  
Interest coverage x29.5163.7 18.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.4 37.2%   
Return on assets %7.616.8 45.1%  
Return on equity %10.723.7 45.1%  
Return on capital %22.236.9 60.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61369 16.4%   
Fx outflow Rs m3,6303,807 95.4%   
Net fx Rs m-3,570-3,438 103.8%   
CASH FLOW
From Operations Rs m1,6101,527 105.4%  
From Investments Rs m687-2,148 -32.0%  
From Financial Activity Rs m-2,677-1,024 261.3%  
Net Cashflow Rs m-380-1,646 23.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 7.9 25.3%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.1 125.7%  
Shareholders   41,647 18,270 228.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Yes Bank Falls Over 10%(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 1.6% while the Hang Seng is down 0.4%.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2019 12:13 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS